New insights into the pathogenesis and therapeutics of episodic ataxia type 1
- PMID: 26347608
- PMCID: PMC4541215
- DOI: 10.3389/fncel.2015.00317
New insights into the pathogenesis and therapeutics of episodic ataxia type 1
Abstract
Episodic ataxia type 1 (EA1) is a K(+) channelopathy characterized by a broad spectrum of symptoms. Generally, patients may experience constant myokymia and dramatic episodes of spastic contractions of the skeletal muscles of the head, arms, and legs with loss of both motor coordination and balance. During attacks additional symptoms may be reported such as vertigo, blurred vision, diplopia, nausea, headache, diaphoresis, clumsiness, stiffening of the body, dysarthric speech, and difficulty in breathing. These episodes may be precipitated by anxiety, emotional stress, fatigue, startle response or sudden postural changes. Epilepsy is overrepresented in EA1. The disease is inherited in an autosomal dominant manner, and genetic analysis of several families has led to the discovery of a number of point mutations in the voltage-dependent K(+) channel gene KCNA1 (Kv1.1), on chromosome 12p13. To date KCNA1 is the only gene known to be associated with EA1. Functional studies have shown that these mutations impair Kv1.1 channel function with variable effects on channel assembly, trafficking and biophysics. Despite the solid evidence obtained on the molecular mechanisms underlying EA1, how these cause dysfunctions within the central and peripheral nervous systems circuitries remains elusive. This review summarizes the main breakthrough findings in EA1, discusses the neurophysiological mechanisms underlying the disease, current therapies, future challenges and opens a window onto the role of Kv1.1 channels in central nervous system (CNS) and peripheral nervous system (PNS) functions.
Keywords: KCNA1; Kv1.1 potassium channel; channelopathy; episodic ataxia type 1; episodic ataxia type 1 therapy; point mutations.
Figures
Similar articles
-
Identification of a New de Novo Mutation Underlying Regressive Episodic Ataxia Type I.Front Neurol. 2018 Jul 25;9:587. doi: 10.3389/fneur.2018.00587. eCollection 2018. Front Neurol. 2018. PMID: 30140249 Free PMC article.
-
Episodic ataxia type 1 mutations in the KCNA1 gene impair the fast inactivation properties of the human potassium channels Kv1.4-1.1/Kvbeta1.1 and Kv1.4-1.1/Kvbeta1.2.Eur J Neurosci. 2006 Dec;24(11):3073-83. doi: 10.1111/j.1460-9568.2006.05186.x. Eur J Neurosci. 2006. PMID: 17156368
-
Clinical, genetic, and expression studies of mutations in the potassium channel gene KCNA1 reveal new phenotypic variability.Ann Neurol. 2000 Oct;48(4):647-56. Ann Neurol. 2000. PMID: 11026449
-
Kv1.1 Channelopathies: Pathophysiological Mechanisms and Therapeutic Approaches.Int J Mol Sci. 2020 Apr 22;21(8):2935. doi: 10.3390/ijms21082935. Int J Mol Sci. 2020. PMID: 32331416 Free PMC article. Review.
-
Novel Genetic Variants Expand the Functional, Molecular, and Pathological Diversity of KCNA1 Channelopathy.Int J Mol Sci. 2023 May 16;24(10):8826. doi: 10.3390/ijms24108826. Int J Mol Sci. 2023. PMID: 37240170 Free PMC article. Review.
Cited by
-
Therapy of episodic ataxias: case report and review of the literature.Drugs Context. 2019 Mar 11;8:212576. doi: 10.7573/dic.212576. eCollection 2019. Drugs Context. 2019. PMID: 30891074 Free PMC article. Review.
-
Case report: A novel loss-of-function pathogenic variant in the KCNA1 cytoplasmic N-terminus causing carbamazepine-responsive type 1 episodic ataxia.Front Neurol. 2022 Aug 9;13:975849. doi: 10.3389/fneur.2022.975849. eCollection 2022. Front Neurol. 2022. PMID: 36016548 Free PMC article.
-
Clinical and Genetic Overview of Paroxysmal Movement Disorders and Episodic Ataxias.Int J Mol Sci. 2020 May 20;21(10):3603. doi: 10.3390/ijms21103603. Int J Mol Sci. 2020. PMID: 32443735 Free PMC article. Review.
-
Episodic Ataxias: Primary and Secondary Etiologies, Treatment, and Classification Approaches.Tremor Other Hyperkinet Mov (N Y). 2023 Mar 28;13:9. doi: 10.5334/tohm.747. eCollection 2023. Tremor Other Hyperkinet Mov (N Y). 2023. PMID: 37008993 Free PMC article. Review.
-
Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery.Front Pharmacol. 2016 May 10;7:121. doi: 10.3389/fphar.2016.00121. eCollection 2016. Front Pharmacol. 2016. PMID: 27242528 Free PMC article. Review.
References
-
- Bain J. R., Mackinnon S. E., Hudson A. R., Wade J., Evans P., Makino A., et al. . (1992). The peripheral nerve allograft in the primate immunosuppressed with Cyclosporin A: I. Histologic and electrophysiologic assessment. Plast. Reconstr. Surg. 90, 1036–1046. 10.1097/00006534-199212000-00015 - DOI - PubMed
-
- Begum R., Kullmann D. M. (2011). “Altered presynaptic spike properties in cerebellar basket cells in a mouse model of episodic ataxia type 1,” Program No. 447.15/E26, 2011 Neuroscience Meeting Planner, (Washington, DC: Society for Neuroscience; ). Available online at: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=2773&sKey=2642...
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources